Investigation of the efficacy of the supplement of L-carnitine for the hemodialysis patients.

Investigation of the efficacy of the supplement of L-carnitine for the hemodialysis patients. - Investigation of the efficacy of the supplement of L-carnitine for the hemodialysis patients.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013009

Enrollment

100

Registered

2014-02-01

Start date

2014-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hemodialysis patients with chronic renal failure

Interventions

1: actual drug giving L-carnitine (20mg/kg/dialysis) over 6 months then, 2:placebo giving saline (5ml/dialysis) over 6 months 1:pacebo giving saline (5ml/dialysis) over 6 months then, 2:ac

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1: Patients undergo hemodialysis for more than one year. 2: Patients didn't recieve the carnitine drugs for 6 months before this trial. 3: Petients participate in this trial on their own will.

Exclusion criteria

Exclusion criteria: 1: carnitine allergy 2: pregnant women

Design outcomes

Primary

Measure	Time frame
#1 questionnaire survey(pysical weariness, muscle condition, et al.) #2 regular blood test and chest X-ray #3 test of physical strength #4 muscle mass #5 ERI(erythropoietin resistance index) #6 differential count of carnitine	—

Countries

Japan

Contacts

Public ContactKeisukeYatsu

Yokohama City University Graduate School of Medicine Medical Science and Cardiorenal Medicine

k-yatsu@be.wakwak.com045-787-2511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026